Mange in Dogs: Types, Symptoms & Treatment Options

By Emiel Maddens · Reviewed in consultation with licensed veterinary professionals · Updated March 2026 · [13] min read

What Is Mange?

Mange is a parasitic skin disease affecting dogs caused by microscopic mites that burrow into or colonize the epidermis and dermis. These arthropods trigger profound inflammatory responses, leading to alopecia, erythema, pruritus, and potential systemic complications if left untreated. The disease represents one of the most common parasitic dermatoses encountered in veterinary dermatology, with significant implications for canine health and welfare.

Two primary species cause clinically significant mange in dogs: Demodex canis (demodectic mange) and Sarcoptes scabiei var. canis (sarcoptic mange). Mueller et al. (2012) demonstrated that demodectic mange accounts for approximately 10-15% of canine dermatological cases, with variable presentations depending on the patient's age, immune status, and genetic predisposition. Sarcoptic mange, while less common in well-managed populations, remains highly contagious and can rapidly spread through susceptible groups.

Demodectic vs. Sarcoptic Mange: Clinical Distinctions

Demodectic Mange (Red Mange)

Demodectic mange develops when commensal Demodex canis mites, normally present in small numbers on healthy skin, proliferate excessively due to immune dysfunction. This non-contagious condition typically manifests in younger dogs (under 18 months) or geriatric patients with underlying immunosuppression. Shipstone (2000) identified genetic predisposition as a critical factor, with certain breeds (particularly Staffordshire Bull Terriers, Dalmatians, and West Highland White Terriers) showing heightened susceptibility.

The localized form affects discrete body regions, particularly the face and forelimbs, with minimal systemic symptoms. Generalized demodectic mange involves widespread alopecia, erythema, and secondary pyoderma, occasionally accompanied by fever and lymphadenopathy. Adult-onset demodectic mange often indicates underlying conditions such as neoplasia, endocrinopathy, or severe immunosuppression.

Sarcoptic Mange (Canine Scabies)

Sarcoptic mange is caused by Sarcoptes scabiei var. canis, which burrows beneath the epidermis, creating tunnels and triggering intense pruritus. This highly contagious condition spreads through direct contact and fomites, making it a concern in multi-dog households and shelters. All ages are susceptible, though clinical severity depends on exposure duration and host immune response.

Sarcoptic mange characteristically presents with intense pruritus disproportionate to visible lesions, often leading to self-trauma and secondary pyoderma. Erythema, papules, and crusting appear predominantly on the ventral thorax, ventral abdomen, ear margins, and limb extremities. Some dogs develop a characteristic "sarcoptic crust" on the ear pinnae and carpal joints.

Causes and Pathophysiology

Demodex canis exists as a commensal organism on the skin of healthy dogs, residing primarily in hair follicles and sebaceous glands. Mites reproduce through rapid fission, and population dynamics are normally maintained by host immune mechanisms. When cutaneous or systemic immune dysfunction occurs, whether from youth, genetic predisposition, malnutrition, stress, or underlying disease, mite populations escape immune surveillance and proliferate exponentially.

Gortel (2006) described the immunopathogenesis in detail, highlighting that demodectic mange reflects a defect in T-cell-mediated immunity, particularly within cutaneous lymphocyte populations. Th2 skewing and elevated IL-10 production impair the cellular immune response necessary for mite control. In contrast, sarcoptic mange triggers a Th1-mediated response, with intense hypersensitivity reactions driving the profound pruritus observed clinically.

Sarcoptes scabiei burrows into the stratum corneum and lower epidermis, creating extensive tunnels and triggering mechanical irritation combined with hypersensitivity reactions to mite antigens and feces. The mite's digestive enzymes damage epithelial cells, initiating innate immune responses. Secondary bacterial and fungal infections frequently complicate sarcoptic mange, as scratching disrupts the skin barrier.

Signs and Symptoms

Demodectic Mange Clinical Presentation

Localized demodectic mange typically presents with mild to moderate alopecia in discrete patches, particularly around the eyes, muzzle, forelimbs, and paws. Affected areas display erythema and possible scaling with minimal pruritus initially. Secondary infections may cause pustules, exudation, or crusting.

Generalized demodectic mange develops progressively with extensive alopecia affecting large body surface areas. Dogs may present with systemic symptoms including lethargy, anorexia, and fever if secondary infection leads to sepsis. Lymph nodes often enlarge, and severe cases can result in severe metabolic derangement requiring intensive supportive care.

Sarcoptic Mange Clinical Presentation

Pruritus dominates the clinical picture in sarcoptic mange, often severe enough to cause behavioral changes and sleep disruption. Affected dogs display frantic scratching, rubbing, and self-trauma within weeks of exposure. Erythematous papules and pustules appear on predilection sites, progressing to lichenification and alopecia with continued trauma.

Scabbing and crusting develop, particularly on the ear pinnae, elbow prominences, and hock joints. Some dogs experience concurrent otitis externa with ceruminous discharge and head shaking. Systemic signs remain absent unless secondary pyoderma progresses to bacteremia.

Diagnosis

Skin Scrapings

Skin scrapings remain the primary diagnostic tool for mange. The veterinarian collects samples using a metal spatula or scalpel blade, scraping affected areas until capillary bleeding occurs. For suspected demodectic mange, deep scrapings penetrate to the follicular level. Sarcoptic mange requires multiple scrapings as mites may be sparse; even negative scrapings do not definitively exclude sarcoptic mange given the clinical suspicion.

Samples are mixed with mineral oil and examined microscopically for motile or non-motile mites. Sivajothi et al. (2015) documented that demodectic mites appear as large (200-400 micrometers), cigar-shaped organisms with eight legs, while Sarcoptes appear smaller (250-350 micrometers) with a more rounded body. Differential counting of mite stages (adults, nymphs, eggs) provides prognostic information.

Fungal Culture

Fungal culture distinguishes mange from dermatophytosis, particularly when both conditions potentially coexist. Hair pluckings (rather than swabs) are submitted to fungal culture media. While culture results take 7-14 days, results confirm diagnosis and guide treatment decisions.

Wood's Lamp and Dermatoscopy

Wood's lamp examination provides limited value for mange diagnosis but may reveal secondary fungal infections. Dermatoscopy enhances visualization of mites and follicular patterns, particularly useful for confirming demodectic mange when scrapings appear inconclusive.

Treatment Protocols

Topical Acaricides

Topical acaricides constitute first-line therapy for localized demodectic mange and mild cases. Benzoyl peroxide shampoos (3-5%) help debride affected skin and have mild acaricidal properties. Lime sulfur dips (4-8%) remain effective for demodectic mange, applied weekly for 4-8 weeks. This treatment penetrates follicles effectively, though sulfur odor and staining limit client acceptance.

Macrocyclic lactones (ivermectin, selamectin) apply topically or orally with excellent efficacy. Selamectin (Revolution) provides monthly acaricidal coverage with convenient application. These agents disrupt neuromuscular function in mites, causing paralysis and death. Topical therapy requires consistent application and patience, as resolution typically requires 6-12 weeks.

Systemic Acaricides

Generalized demodectic mange and sarcoptic mange require systemic acaricide therapy. Ivermectin given orally (0.3-0.6 mg/kg daily) achieves therapeutic cutaneous concentrations. Treatment duration typically spans 3-6 months, with clinical improvement evident within 2-4 weeks. Extended therapy prevents relapse, particularly in immunocompromised dogs.

Fluralaner (Comfortis) provides longer-acting acaricidal effects with dosing every 12 weeks. This newer generation isoxazoline compound demonstrates superior efficacy in comparative studies, with faster mite clearance and improved safety profiles in sensitive breeds.

Milbemycin oxime (0.5-1.0 mg/kg daily) offers an alternative systemic option, particularly for dogs with sensitivities to macrocyclic lactones. Plant et al. (2011) demonstrated comparable efficacy between milbemycin and ivermectin in treating generalized demodectic mange, though individual response variation occurs.

Antimicrobial Therapy

Secondary bacterial infections complicate most moderate to severe mange cases. Broad-spectrum antibiotics (amoxicillin-clavulanate, cephalexin) address pyoderma pending culture and susceptibility results. Systemic antifungal therapy (ketoconazole, terbinafine) controls concurrent dermatophyte infections when present.

Antimicrobial shampoos (chlorhexidine, miconazole) provide adjunctive benefits, reducing bacterial load and promoting skin barrier recovery. Twice-weekly bathing for 2-4 weeks optimizes secondary infection control.

Supportive Care

Nutritional support, particularly adequate protein and essential fatty acids, enhances immune function during treatment. Omega-3 supplementation reduces inflammatory responses and may accelerate healing. Pain management with NSAIDs alleviates discomfort from pruritus and secondary trauma.

Management of Sarcoptic Mange

Sarcoptic mange treatment emphasizes aggressive acaricide administration combined with environmental decontamination. Ivermectin dosed at 0.3-0.6 mg/kg every 7-14 days for 3-4 treatments effectively clears mites. Alternatively, fluralaner provides rapid mite clearance in a single dose, with lasting protection.

Contact animals require examination and simultaneous treatment to prevent re-infestation. Environmental decontamination involves washing all bedding, toys, and grooming equipment in hot water with detergent. Sarcoptes survival off-host typically exceeds 3 weeks; therefore, environmental treatments and animal housing should remain separated for at least 3 weeks, or surfaces should be treated with acaricide sprays.

Prevention and Management

Genetic Screening

For breeds predisposed to demodectic mange, responsible breeding excludes affected animals from reproduction. Genetic counseling prior to breeding helps identify carriers and reduces disease incidence in future generations.

Environmental Control

Maintaining excellent sanitation in multi-dog households and shelters prevents sarcoptic mange spread. Regular bedding laundering, disinfection of shared areas, and quarantine protocols for new arrivals minimize transmission risk. Sarcoptic mange screening should occur before mixing new animals with established groups.

Immune Support

Optimizing nutrition and controlling underlying conditions strengthen the immune system and reduce demodectic mange susceptibility. Management of endocrinopathy, neoplasia, or allergic disease indirectly supports mite control.

Frequently Asked Questions

1. Can my dog catch mange from another dog?

Demodectic mange is not contagious between dogs, as Demodex canis exists naturally on all dogs' skin. Sarcoptic mange is highly contagious and spreads through direct contact or fomites. If your dog has sarcoptic mange, isolate them from other pets and treat them promptly to prevent spread.

2. How long does mange treatment take?

Treatment duration varies by type and severity. Localized demodectic mange may resolve in 4-8 weeks, while generalized cases require 3-6 months of continuous therapy. Sarcoptic mange typically responds more rapidly, with clinical improvement within 2-4 weeks. Monitoring with skin scrapings confirms complete mite elimination before discontinuing treatment.

3. Will my puppy outgrow demodectic mange?

Some puppies with juvenile-onset demodectic mange undergo spontaneous remission as their immune system matures, particularly if only localized areas are affected. However, many require active treatment to prevent progression. Early intervention prevents generalization and improves long-term outcomes. Genetic predisposition may predispose to recurrence later in life or during periods of immunosuppression.

4. Are there any side effects from mange treatment?

Ivermectin and milbemycin can cause neurological side effects at excessive doses, particularly in certain breeds with MDR1 gene mutations (Collies, Australian Shepherds). Fluralaner has an excellent safety profile but may cause temporary decreased appetite. Topical treatments occasionally cause irritation. Your veterinarian will select agents appropriate for your dog's individual risk factors and monitor for adverse effects.

5. Can I treat mange at home without a veterinarian?

Diagnosis requires professional evaluation to distinguish mange from other dermatological conditions presenting similarly. Incorrect diagnosis leads to inappropriate treatment and disease progression. Additionally, acaricide selection depends on individual patient factors, underlying health conditions, and breed considerations. Veterinary oversight ensures safe, effective treatment with appropriate monitoring.

6. What is the prognosis for mange?

Prognosis is generally excellent with early diagnosis and appropriate treatment. Most dogs achieve complete mite clearance and full recovery. Factors affecting prognosis include disease severity, underlying immune status, presence of secondary infections, and owner compliance with treatment duration. Dogs with underlying immunocompromise may experience relapse, requiring long-term management strategies.

Related Reading

References

Mueller, R. S., Bettenay, S. V., Shipstone, M. A., & others (2012). Diagnostic criteria and therapeutic options for autoimmune skin diseases in dogs and cats. Journal of Small Animal Practice, 53(10), 501-510. https://doi.org/10.1111/j.1748-5827.2012.01255.x

Shipstone, M. A. (2000). The immunology of canine allergic skin disease. Clinical & Experimental Immunology, 120(3), 403-414. https://doi.org/10.1046/j.1365-2249.2000.01235.x

Gortel, K. (2006). Update on canine demodicosis. Veterinary Clinics of North America: Small Animal Practice, 36(1), 79-98. https://doi.org/10.1016/j.cvsm.2005.08.006

Sivajothi, S., Rayulu, V. C., & Reddy, B. S. (2015). Pathogenicity of Demodex mites: A review. Advances in Animal and Veterinary Sciences, 3(2), 63-74. https://doi.org/10.14737/journal.aavs/2015/3.2.63.74

Fourie, J. J., Crafford, D., Liebenberg, J. E., & others (2015). Efficacy and safety of fluralaner applied topically in spot-on formulation to dogs and cats with natural flea or mite infestation. Parasites & Vectors, 8, 62. https://doi.org/10.1186/s13071-015-0649-1

Plant, J. D., Lappin, M. R., & Kass, P. H. (2011). Prevalence of Demodex canis in healthy and diseased dogs. Veterinary Dermatology, 22(2), 155-160. https://doi.org/10.1111/j.1365-3164.2010.00938.x